We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+8.6%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.35B
AUM Growth
+$157M
Cap. Flow
+$100M
Cap. Flow %
7.42%
Top 10 Hldgs %
27.65%
Holding
142
New
12
Increased
63
Reduced
5
Closed
5

Top Buys

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$21.7M
2
CI icon
Cigna
CI
+$11.2M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$10.4M
4
CLSD
Clearside Biomedical
CLSD
+$9.46M
5
HOLX
Hologic
HOLX
+$7.96M

Top Sells

Rank Stock Value
1
BXLT
BAXALTA INC COM STK (DE)
BXLT
+$32.7M
2
ELV icon
Elevance Health
ELV
+$16.8M
3
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$9.49M
4
COO icon
Cooper Companies
COO
+$7.33M
5
INOV
Inovalon Holdings, Inc. Class A Common Stock
INOV
+$5.78M

Sector Composition

Rank Sector Weight
1 Healthcare 77.95%
2 Financials 3.98%
3 Industrials 0.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EW icon
51
Edwards Lifesciences
EW
$51.7B
$8.33M 0.62%
250,500
+22,500
+10% +$770K
HOLX
52
DELISTED
Hologic
HOLX
$7.96M 0.59%
+230,000
New +$7.96M
MCRB icon
53
Seres Therapeutics
MCRB
$48.4M
$7.61M 0.56%
13,100
– –
JUNO
54
DELISTED
Juno Therapeutics, Inc.
JUNO
$7.57M 0.56%
197,001
– –
EVHC
55
DELISTED
Envision Healthcare Holdings Inc
EVHC
$7.38M 0.55%
97,194
+8,350
+9% +$593K
ITCI
56
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$7.38M 0.55%
190,000
+2,500
+1% +$89.8K
VRTX icon
57
Vertex Pharmaceuticals
VRTX
$126B
$7.36M 0.54%
85,500
+1,600
+2% +$138K
ISEE
58
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$7.27M 0.54%
142,500
+91,000
+177% +$4.52M
ARA
59
DELISTED
American Renal Associates Holdings, Inc
ARA
$7.24M 0.54%
+250,000
New +$6.96M
RARE icon
60
Ultragenyx Pharmaceutical
RARE
$2.55B
$6.92M 0.51%
141,500
+23,000
+19% +$1.49M
CHRS icon
61
Coherus Oncology
CHRS
$196M
$6.76M 0.5%
400,000
+118,000
+42% +$2.22M
ONC
62
BeOne Medicines Ltd
ONC
$39.4B
$6.71M 0.5%
225,000
– –
SRGA
63
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$6.68M 0.49%
62,000
– –
CRVS icon
64
Corvus Pharmaceuticals
CRVS
$1.17B
$6.42M 0.48%
450,000
-6,887
-2% -$93K
NVTA
65
DELISTED
Invitae Corporation
NVTA
$6.34M 0.47%
858,380
+105,880
+14% +$987K
FPRX
66
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$6.33M 0.47%
153,000
+8,500
+6% +$370K
ATHN
67
DELISTED
Athenahealth, Inc.
ATHN
$6.31M 0.47%
45,750
– –
ADAP
68
DELISTED
Adaptimmune Therapeutics
ADAP
$6.24M 0.46%
765,001
– –
NVAX icon
69
Novavax
NVAX
$1.31B
$6.2M 0.46%
42,625
– –
CORV
70
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$6.14M 0.45%
1,200,000
+10,000
+0.8% +$48K
EPZM
71
DELISTED
Epizyme, Inc
EPZM
$6.12M 0.45%
597,500
+8,500
+1% +$94.8K
MGNX icon
72
MacroGenics
MGNX
$257M
$6.07M 0.45%
225,000
– –
HRC
73
DELISTED
HILL-ROM HOLDINGS, INC.
HRC
$6.05M 0.45%
+120,000
New +$6.05M
REGN icon
74
Regeneron Pharmaceuticals
REGN
$80.8B
$5.94M 0.44%
17,000
+500
+3% +$193K
PRTK
75
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$5.82M 0.43%
418,500
+195,500
+88% +$2.88M
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2016 Portfolio in Review

As of Q2 2016, Rock Springs Capital Management held 142 positions worth $1.35B, up 13% from $1.19B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Rock Springs Capital Management deployed $100M of net new capital in Q2 2016, opening 12 new positions and adding to 63 existing holdings. Its largest new stake was Shire pic: 120,042 shares worth $22.1M.

By sector, the portfolio is most concentrated in Healthcare at 78% of assets, up from 78% a quarter earlier, followed by Financials and Industrials.

On the sell side, the largest reduction was Inovalon Holdings, Inc. Class A Common Stock, an estimated $5.78M trimmed.

  • Rock Springs Capital Management's largest Q2 2016 buy was Shire pic: 120,042 shares worth $22.1M.
  • Rock Springs Capital Management added most to Cigna in Q2 2016, an estimated $11.2M increase.
  • Rock Springs Capital Management's biggest Q2 2016 reduction was Inovalon Holdings, Inc. Class A Common Stock, cutting an estimated $5.78M.
  • Rock Springs Capital Management fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $32.7M.
  • Rock Springs Capital Management's ten largest holdings make up 28% of its $1.35B portfolio in Q2 2016.
  • Rock Springs Capital Management opened 12 new positions and closed 5 in Q2 2016.
  • Rock Springs Capital Management's portfolio value rose 13% quarter-over-quarter to $1.35B.

Based on Rock Springs Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.